Modulari-T GTM brain

Modulari-T develops engineered immune receptors and delivery vectors for next-generation cell therapies, with potential pharmaceutical development partners.

category

Cell and gene therapy platforms

market profile

  • text: First-generation cell therapies face toxicity, exhaustion, relapse, manufacturing and solid tumor limitations, according to the company.
  • text: Its MARC receptor and MoVe delivery platform aim at in vivo and engineered cell therapy applications; partnership use cases are an inference, not a confirmed commercial offer.

personas

  • title: Cell therapy research and development leader
    pains:
    • Needs controllable immune activation and durable cell function
    • Must translate promising receptor designs beyond blood cancers
  • title: Biopharma business development and licensing leader
    pains:
    • Needs differentiated technology that can complement an oncology pipeline
    • Must assess translational evidence, intellectual property and partnership fit

icp

  • text: Biopharmaceutical companies developing engineered immune cell therapies in oncology, especially solid tumors; inferred prospective partners.
  • text: Cell and gene therapy developers investigating in vivo delivery or receptor engineering; account size and actual licensing terms are unconfirmed.

message pillars

  • text: Separate targeting from signaling in a modular receptor.
  • text: Offer control over receptor activity.
  • text: Target immune or non-immune cells with a delivery vehicle.

objections

  • objection: Will the approach work in humans and solid tumors?
    response: Review preclinical data, disease-specific translational plans and trial status; the website does not establish clinical efficacy.
  • objection: Can it be manufactured and delivered safely at scale?
    response: Request vector biodistribution, manufacturing, toxicology and comparability data before evaluating a partnership.

competitors

  • name: Arcellx
    why: Develops engineered cell therapies and is identified as a possible competitor by Crunchbase.
  • name: Synthekine
    why: Develops immunotherapies and is identified as a possible competitor by Crunchbase.

keywords

  • engineered immune receptors
  • in vivo cell therapy
  • CAR T solid tumors
  • cell therapy exhaustion
  • targeted gene delivery
  • cell therapy licensing

voice

  • scientific
  • ambitious
  • problem-led

signals

  • text: An oncology developer is expanding from hematologic cancers into solid tumors.
  • text: A cell therapy program is seeking more controllable receptor signaling or in vivo delivery.

pricing

model: unknown

motion

unknown

channels

  • LinkedIn
  • industry events

confidence

medium

Founders

  • name: David White
    title: Founder
    role: Founder
    bio: David is the CEO and cofounder of Modulari-T. His expertise spans multiple areas and he is driven by a passion for pushing the boundaries of technology. During his PhD he discovered how protein receptors form complex structures that allow them to alter cells’ behavior. He then took this knowledge and the novel technology that was developed to build Modulari-T. When he’s not thinking up a new way to engineer cells he can be spotted biking or running up a mountain.
  • name: Stephanie Mok
    title: Founder
    role: Founder
    bio: Co-founder and COO at Modulari-T. PhD in chemical engineering. Technical background in synthetic biology, advanced 3D cell culture systems, and biomaterials in the context of the cellular cancer microenvironment. Fascinated by the innovations cell-based therapies, food products, and the scale up of their manufacturing. Gave the unconference talk "Lessons learned and mistakes made growing the world's hottest peppers".

Back to YC companies